Eribulin
- Generic Name
- Eribulin
- Brand Names
- Halaven, Eribulin Baxter, Mevlyq
- Drug Type
- Small Molecule
- Chemical Formula
- C40H59NO11
- CAS Number
- 253128-41-5
- Unique Ingredient Identifier
- LR24G6354G
- Background
Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of advanced solid ...
- Indication
For the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic cancer.
- Associated Conditions
- Metastatic Liposarcoma, Refractory, metastatic Breast cancer, Unresectable Liposarcoma
- Associated Therapies
- -
Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer
- First Posted Date
- 2011-04-04
- Last Posted Date
- 2019-08-20
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 81
- Registration Number
- NCT01328249
- Locations
- 🇺🇸
Dartmouth-Hitchcock Medical Center ,Norris Cotton Cancer Center, Lebanon, New Hampshire, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
A Confirmation Study of Eribulin in Combination With Capecitabine
- Conditions
- Interventions
- First Posted Date
- 2011-03-25
- Last Posted Date
- 2021-01-11
- Lead Sponsor
- Eisai Limited
- Target Recruit Count
- 76
- Registration Number
- NCT01323530
Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer
- First Posted Date
- 2011-01-04
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT01269346
- Locations
- 🇺🇸
Heartland Regional Medical Center, Saint Joseph, Missouri, United States
🇺🇸Texas Oncology - Medical City Dallas, Dallas, Texas, United States
🇺🇸Peachtree Hematology Oncology Associates, PC, Atlanta, Georgia, United States
A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-12-29
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT01268150
- Locations
- 🇺🇸
Northwest Georgia Oncology Centers, P.C., Marietta, Georgia, United States
🇺🇸Augusta Oncology Associates, Augusta, Georgia, United States
🇺🇸Central Georgia Cancer Care, Macon, Georgia, United States
An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory
- Conditions
- First Posted Date
- 2010-11-15
- Last Posted Date
- 2015-05-22
- Lead Sponsor
- Eisai Inc.
- Registration Number
- NCT01240421
Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies
- First Posted Date
- 2010-06-11
- Last Posted Date
- 2013-09-20
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT01142661
Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-05-20
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 98
- Registration Number
- NCT01126736
QT Interval Prolongation Study of Eribulin Mesylate (E7389) in Patients With Advanced Solid Tumors
- First Posted Date
- 2010-04-19
- Last Posted Date
- 2012-04-13
- Lead Sponsor
- Eisai Limited
- Target Recruit Count
- 26
- Registration Number
- NCT01106248
- Locations
- 🇫🇷
Medicale, Dunkerque, *CS, France
🇫🇷Service d'Oncologie, Dunkerque, *CS, France
Study of E7389 for Advanced or Metastatic Breast Cancer
- First Posted Date
- 2009-08-25
- Last Posted Date
- 2013-08-15
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 81
- Registration Number
- NCT00965523
A Study to Determine the Metabolism and Elimination of Carbon-14 Labeled Eribulin Acetate (14C-Eribulin) in Patients With Advanced Solid Tumors
- First Posted Date
- 2009-05-27
- Last Posted Date
- 2012-03-09
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT00908908
- Locations
- 🇳🇱
Netherlands Cancer Institute, Amsterdam, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.